Merck KGaA, the German maker of Erbitux cancer medicine, promoted Stefan Oschmann to deputy chief executive officer and appointed Belen Garijo as its first female board member. Oschmann, currently head of the pharmaceutical unit, and Garijo, now ... BusinessWeek, 4 days ago
Merck KGaA Names Pharmaceutical Chief Oschmann as Deputy CEO - Washington Post, 4 days ago
3 images for "erbitux"
Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Revision: 23, Authorised
Erbitux : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 2009-07-14 2014-08-14 ...European Medicines Agency, 1 month ago
Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors
Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive non-small cell lung (NSCLC)cancer that had ...CancerConnect.com, 1 month ago New treatment combination benefited patients with lung cancer resistant to EGFR inhibitors Ecancer Medicalscience, 1 month ago New Treatment Combination Benefits Patients With EGFR Inhibitors Advance for Respiratory Care & Sleep Medicine, 1 month ago Afatinib plus cetuximab shows promise for EGFR -mutated lung cancer Orthopedics Today, 1 month ago
By Daniel Michaels And Shayndi Raice FRANKFURT--German companies are on a buying spree--and the U.S. is their biggest target. On Monday, pharmaceutical firm Merck KGaA said it would buy Sigma Aldrich Corp., a life-sciences company based in St.4 Traders, 2 hours ago
More from: ADVFN India, Nasdaq...and 3 other sources
Summary Merck announced Monday that it would acquire Sigma-Aldrich for $17 billion. The deal marks the largest takeover in Merck's history, and it could be its most successful. Acquiring Sigma-Aldrich allows Merck to develop its chemicals ...Seeking Alpha, 7 hours ago Merck KGaA pays out $17 billion for Sigma-Aldrich Pharmafocus, 9 hours ago Merck KGaA to Acquire Sigma-Aldrich for $17B in Cash Mergers & Acquisitions, 11 hours ago Merck KGaA to Buy Sigma-Aldrich for $17 Billion to Add Chemicals BusinessWeek, 12 hours ago
Pipeline Progress Announced 22-09-2014: Merck announced that its biopharmaceutical division Merck Serono is well on track with the implementation of the Group's Fit for 2018 transformation and growth program. This is reflected by efficiency gains ...Bionity.com, 20 hours ago Merck KGaA : on Track with Pharma Strategy; Pipeline Progress Announced 4 Traders, 4 days ago Merck KGaA Says On Track With Pharma Strategy Pharmacy Choice, 4 days ago MERCK KGAA : acute;s Biopharmaceutical Division Announces Groundbreaking of New Pharmaceutical Manufacturing Facility in China, its Second Largest Worldwide 4 Traders, 3 weeks ago
Merck KGaA ( MKGAF ) provided an update on its Fit for 2018 transformation and growth program. The company said that its biopharmaceutical division, Merck Serono, remains on track for the program. The company discussed its plans regarding the ...Yahoo! Finance, 3 days ago
Dr. Annalisa Jenkins CAMBRIDGE, MASS., September 16, 2014 Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, today announced that Annalisa Jenkins, MBBS, MRCP has been appointed as chief ...BioSpace, 6 days ago Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer Crawford Financial Planning, 6 days ago Dimension Therapeutics : Names Annalisa Jenkins as Chief Executive Officer 4 Traders, 6 days ago
By | CNBC The easiest million dollars I ever made in the market was beneath the rubble of Martha Stewart and Sam Waksal. It was late December 2001, and the people in the know had already sold their shares of ImClone due to the FDA's rejection ...Yahoo! Malaysia, 6 days ago
The addition of cetuximab to cisplatin-based radiation therapy conferred no significant benefit with regard to PFS, OS, locoregional failure or distant metastasis in patients with stage III or stage IV head and neck carcinoma, according to results ...Orthopedics Today, 1 week ago Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234 Journal of Clinical Oncology, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!